Department of Nuclear Medicine, Centre for Clinical Cardiovascular Science, Nuffield House, Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, Edgbaston, B15 2TH, UK.
Department of Nuclear Medicine, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Oxford Road, Manchester, M13 9WL, UK.
J Nucl Cardiol. 2021 Dec;28(6):2876-2891. doi: 10.1007/s12350-020-02126-z. Epub 2020 May 11.
Although consensus-based guidelines support noninvasive stress testing prior to orthotopic liver transplantation (OLT), the optimal screening strategy for assessment of coronary artery disease in patients with end-stage liver disease (ESLD) is unclear. This study sought to determine the relative predictive value of coronary risk factors, functional capacity, and single photon emission computed tomography (SPECT) on major adverse cardiovascular events and all-cause mortality in liver transplantation candidates.
Prior to listing for transplantation, 404 consecutive ESLD patients were referred to a University hospital for cardiovascular (CV) risk stratification. All subjects met at least one of the following criteria: inability to perform > 4 METs by history (62%), insulin-treated diabetes mellitus (53%), serum creatinine > 1.72 mg/dL (8%), history of MI, PCI or CABG (5%), stable angina (3%), cerebrovascular disease (1%), peripheral vascular disease (1%). Subjects underwent Technetium-99m SPECT with multislice coronary artery calcium scoring (CACS) using exercise treadmill or standard adenosine stress in those unable to achieve 85% maximal heart rate (Siemens Symbia T16). Abnormal perfusion was defined as a summed stress score (SSS) ≥ 4.
Of the 404 patients, 158 (age 59 ± 9 years; male 68%) subsequently underwent transplantation and were included in the primary analysis. Of those, 50 (32%) died after a mean duration follow-up of 5.4 years (maximal 10.9 years). Most deaths (78%) were attributed to noncardiovascular causes (malignancy, sepsis, renal failure). Of the 32 subjects with abnormal perfusion (20%), nine (6%) had a high-risk perfusion abnormality defined as a total perfusion defect size (PDS) ≥ 15% and/or an ischemic PDS ≥ 10%. Kaplan-Meier survival curves demonstrated abnormal perfusion was associated with increased CV mortality (generalized Wilcoxon, P = 0.014) but not all-cause death. Subjects with both abnormal perfusion and an inability to exercise > 4 METs had the lowest survival from all-cause death (P = 0.038). Abnormal perfusion was a strong independent predictor of CV death (adjusted HR 4.2; 95% CI 1.4 to 12.3; P = 0.019) and MACE (adjusted HR 7.7; 95% CI 1.4 to 42.4; P = 0.018) in a multivariate Cox regression model that included age, sex, diabetes, smoking and the ability to exercise > 4 METs. There was no association between CACS and the extent of perfusion abnormality, nor with outcomes.
Most deaths following OLT are noncardiovascular. Nonetheless, abnormal perfusion is prevalent in this high-risk population and a stronger predictor of cardiovascular morbidity and mortality than functional status. A combined assessment of functional status and myocardial perfusion identifies those at highest risk of all-cause death. (Exercise Capacity and Single Photon Emission Computed Tomography in Liver Transplantation Candidates [ExSPECT]; ClinicalTrials.gov Identifier: NCT03864497).
尽管基于共识的指南支持在原位肝移植(OLT)前进行非侵入性应激测试,但对于终末期肝病(ESLD)患者评估冠状动脉疾病的最佳筛查策略尚不清楚。本研究旨在确定冠状动脉危险因素、功能能力和单光子发射计算机断层扫描(SPECT)在肝移植候选者的主要不良心血管事件和全因死亡率方面的相对预测价值。
在接受移植之前,404 名连续的 ESLD 患者被转介到一所大学医院进行心血管(CV)风险分层。所有患者至少符合以下标准之一:病史无法进行 > 4 METs(62%)、胰岛素治疗的糖尿病(53%)、血清肌酐 > 1.72mg/dL(8%)、心肌梗死史、经皮冠状动脉介入治疗或冠状动脉旁路移植术(5%)、稳定型心绞痛(3%)、脑血管病(1%)、外周血管病(1%)。患者接受 99mTc 标记的 SPECT 检查,使用运动跑步机或无法达到最大心率 85%的标准腺苷应激进行多排冠状动脉钙评分(CACS)(西门子 Symbia T16)。异常灌注定义为总和应激评分(SSS)≥4。
在 404 名患者中,有 158 名(年龄 59±9 岁;男性 68%)随后接受了移植,并纳入了主要分析。其中,50 名(32%)在平均随访 5.4 年后死亡(最长 10.9 年)。大多数死亡(78%)归因于非心血管原因(恶性肿瘤、脓毒症、肾衰竭)。在 32 名存在异常灌注的患者中(20%),有 9 名(6%)存在高风险灌注异常,定义为总灌注缺陷大小(PDS)≥15%和/或缺血性 PDS≥10%。Kaplan-Meier 生存曲线表明异常灌注与 CV 死亡率增加相关(广义 Wilcoxon,P=0.014),但与全因死亡无关。同时存在异常灌注和无法进行 > 4 METs 运动的患者全因死亡率最低(P=0.038)。异常灌注是 CV 死亡的强独立预测因素(调整后的 HR 4.2;95%CI 1.4 至 12.3;P=0.019)和 MACE(调整后的 HR 7.7;95%CI 1.4 至 42.4;P=0.018),在包括年龄、性别、糖尿病、吸烟和能够进行 > 4 METs 运动的多变量 Cox 回归模型中。CACS 与灌注异常的程度之间没有关联,也与结果没有关联。
OLT 后大多数死亡是非心血管原因。尽管如此,异常灌注在这一高危人群中很常见,并且是心血管发病率和死亡率的更强预测因素,而不是功能状态。功能状态和心肌灌注的联合评估可以识别出全因死亡风险最高的患者。(肝移植候选者的运动能力和单光子发射计算机断层扫描[ExSPECT];临床试验标识符:NCT03864497)。